Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $668.0K | $12.7M |
| Cost of revenue | $0 | $0 | $691.0K | $6.5M |
| Gross profit | $0 | $0 | −$23.0K | $6.2M |
| Gross margin | — | — | -3.4% | 48.7% |
| R&D | $28.8M | $27.3M | $20.6M | $11.5M |
| Operating income | −$41.6M | −$45.3M | −$71.5M | −$83.2M |
| EBITDA | −$40.8M | −$44.3M | −$70.4M | −$91.3M |
| Net income | −$41.9M | −$45.8M | −$76.5M | −$129.4M |
| Net margin | — | — | -11457.5% | -1023.1% |
| EPS (diluted) | -3.19 | -3.49 | -5.24 | -5.52 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds IMPL.
No tracked institution reports a position in IMPL as of their last filing.
No one on the platform has traded IMPL yet.
| $1M |
| — |
| CYTOAltamira Therapeutics Ltd. | $0.30 | +100.00% | $1M | — |
| INFIQInfinity Pharmaceuticals, Inc. | $0.00 | +0.00% | $9076 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.